How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

18,453 results for

Thrombocytopenia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Fostamatinib (Tavalisse) - To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP)

Fostamatinib (Tavalisse) - To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP) Drug Approval Package: TAVALISSE (fostamatinib disodium hexahydrate) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TAVALISSE (fostamatinib disodium hexahydrate) Company: Rigel Pharmaceuticals, Inc. Application Number: 209299 Approval Date: 04/17/2018 Persons with disabilities having problems accessing the PDF files below

2018 FDA - Drug Approval Package

2. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure T echnology appraisal guidance Published: 8 January 2020 www.nice.org.uk/guidance/ta617 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

3. Fostamatinib (Tavlesse) - chronic immune thrombocytopenia

Fostamatinib (Tavlesse) - chronic immune thrombocytopenia Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/628301/2019 EMEA/H/C/005012 Tavlesse (fostamatinib) An overview (...) of Tavlesse and why it is authorised in the EU What is Tavlesse and what is it used for? Tavlesse is a medicine for treating adults with chronic immune thrombocytopenia. It is for use when other treatments have not worked. Chronic immune thrombocytopenia, previously called idiopathic thrombocytopenic purpura (ITP), is a long-term condition in which the immune system (the body’s defences) destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding. Patients

2020 European Medicines Agency - EPARs

4. Immune thrombocytopenia

Immune thrombocytopenia Immune thrombocytopenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Immune thrombocytopenia Last reviewed: February 2019 Last updated: March 2019 Summary Immune thrombocytopenia (ITP), also known as immune thrombocytopenic purpura, is defined as an autoimmune haematological disorder characterised by isolated thrombocytopenia in the absence of an identifiable cause. Typically found (...) in children often with a preceding viral illness and an abrupt onset. There is a female preponderance among adults, who may present with thrombocytopenia with or without bleeding. Petechiae occur primarily on the lower limbs, but can appear anywhere on the body (including mucosal membranes), particularly if thrombocytopenia is severe. Bruising is common. Mucosal bleeding may also occur in more severe cases. Intracranial bleeding is reported in less than 1% of adults and less than 0.5% of children. Full

2019 BMJ Best Practice

5. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT)

Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) - Regan - - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term RCOG Scientific Impact Paper Free Access Prenatal Management of Pregnancies (...) at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) Scientific Impact Paper No. 61 on behalf of Corresponding Author E-mail address: Correspondence : Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG, UK. Email: on behalf of Corresponding Author E-mail address: Correspondence : Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG, UK. Email: First published: 09 April 2019 Give access Share full text

2019 Royal College of Obstetricians and Gynaecologists

6. Lusutrombopag - to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease

Lusutrombopag - to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/889817/2018 (...) EMEA/H/C/004720 Lusutrombopag Shionogi (lusutrombopag) An overview of Lusutrombopag Shionogi and why it is authorised in the EU What is Lusutrombopag Shionogi and what is it used for? Lusutrombopag Shionogi is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding. The medicine is for use

2019 European Medicines Agency - EPARs

7. Diagnosis and management of heparin?induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group

Diagnosis and management of heparin?induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range (...) to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group Joanne Joseph, David Rabbolini, Anoop K Enjeti, Emmanuel Favaloro, Marie‐Christine Kopp

2019 MJA Clinical Guidelines

8. Heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia Heparin-induced thrombocytopenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Heparin-induced thrombocytopenia Last reviewed: February 2019 Last updated: May 2018 Summary A severe drug reaction to heparin that can lead to life- and limb-threatening venous and/or arterial thromboembolism. Diagnosis requires the combination of a compatible clinical picture and laboratory confirmation (...) of the presence of heparin-dependent platelet-activating HIT antibodies. Neither discontinuation of heparin alone nor initiation of a vitamin K antagonist alone (e.g., warfarin) is sufficient to stop the development of thrombosis in a patient with acute HIT. If clinical suspicion for HIT is at least moderate, all sources of heparin (including low molecular weight heparin) must be discontinued and initiation of treatment with a non-heparin anticoagulant considered. Definition Heparin-induced thrombocytopenia

2018 BMJ Best Practice

9. Assessment of thrombocytopenia

Assessment of thrombocytopenia Assessment of thrombocytopenia - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of thrombocytopenia Last reviewed: February 2019 Last updated: June 2018 Summary Thrombocytopenia is defined as a low circulating platelet count (<150,000 per microlitre). Platelet life span is normally approximately 5 days, with continual renewal. True thrombocytopenia results from either (...) a reduced production of platelets in the bone marrow, increased clearance, or sequestering of platelets in the spleen. Epidemiology The causes of thrombocytopenia are diverse, making epidemiological generalisations difficult. However, immune thrombocytopenia (ITP) is typically an illness of young women. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-186. http

2018 BMJ Best Practice

10. Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. Full Text available with Trip Pro

Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. People with a low platelet count (thrombocytopenia) often require lumbar punctures or an epidural anaesthetic. Lumbar punctures can be diagnostic (haematological malignancies, subarachnoid haematoma, meningitis) or therapeutic (spinal anaesthetic, administration of chemotherapy). Epidural catheters are placed for administration of epidural (...) anaesthetic. Current practice in many countries is to correct thrombocytopenia with platelet transfusions prior to lumbar punctures and epidural anaesthesia, in order to mitigate the risk of serious procedure-related bleeding. However, the platelet count threshold recommended prior to these procedures varies significantly from country to country. This indicates significant uncertainty among clinicians regarding the correct management of these patients. The risk of bleeding appears to be low

2018 Cochrane

11. Avatrombopag (Doptelet) - To treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure

Avatrombopag (Doptelet) - To treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure Drug Approval Package: Doptelet (avatrombopag) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Doptelet (avatrombopag) Company: AkaRx, Inc. Application Number: 210238 Approval Date: 05/21/2018 Persons with disabilities having problems accessing the PDF files below may call (301

2018 FDA - Drug Approval Package

12. Diagnosis and management of typical, newly diagnosed primary immune thrombocytopenia (ITP) of childhood

Diagnosis and management of typical, newly diagnosed primary immune thrombocytopenia (ITP) of childhood This practice point applies to children aged 90 days through 17 years who have typical, newly diagnosed primary immune thrombocytopenia (ITP).  Current recommendations on management and information from recent studies are summarized with the goal of decreasing variable practice among providers and improving patient-centred care. Options for initially managing young patients (...) . Keywords: Intracranial hemorrhage (ICH); Immune thrombocytopenia (ITP); Intravenous immunoglobulin (IVIG); Shared decision-making (SDM)

2018 Canadian Paediatric Society

13. Lusutrombopag (Mulpleta) - To treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

Lusutrombopag (Mulpleta) - To treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure Drug Approval Package: Mulpleta (lusutrombopag) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Mulpleta (lusutrombopag) Company: Shionogi Inc. Application Number: 210923 Approval Date: 07/31/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA

2018 FDA - Drug Approval Package

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>